Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Propylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propylene Glycol SCHEMBL159499 | 1.00 | — | — | |
| Propylene Glycol SCHEMBL156298 | 1.00 | — | — | |
| Propylene Glycol SCHEMBL3664673 | 1.00 | — | — | |
| Propylene Glycol SCHEMBL1985568 | 1.00 | — | — | |
| Propylene Glycol SCHEMBL10332456 | 1.00 | TDP1 (0.91) | — | |
| Propylene Glycol SCHEMBL5051858 | 1.00 | TDP1 (0.91) | — | |
| Propylene Glycol SCHEMBL1988316 | 0.96 | — | — | |
| Propylene Glycol SCHEMBL29058944 | 0.96 | — | — | |
| Propylene Glycol SCHEMBL11140327 | 0.96 | — | — | |
| Propylene Glycol SCHEMBL28330090 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 955 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078311-A1 | ACTIVELY COOLED SCREW FEEDER FOR GASIFICATION REACTORS | ARIES CLEAN TECH LLC (US) | 2026-03-19 | — | — | US | claimed |
| CN-121569820-A | Preparation method of degradable bactericide for oil field | 东营江源化工有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-20260028969-A1 | SYSTEM AND PROCESS FOR EXTRACTING ENERGY FROM HEAT | SHELLEF HOLDINGS INC (US) | 2026-01-29 | — | — | US | claimed |
| US-12467380-B1 | System and process for extracting energy from heat | SHELLEF HOLDINGS INC. (US) | 2025-11-11 | — | — | US | claimed |
| WO-2025132901-A1 | Bilayer tablet formulation comprising dapagliflozin and metformin | KRKA, D.D., NOVO MESTO (SI) | 2025-06-26 | — | — | WO | claimed |
| EP-4560244-A1 | STORAGE DEVICE AND USE OF SUCH A STORAGE DEVICE AS AN ENERGY STORAGE DEVICE IN A BUILDING SUPPLY SYSTEM | PVT Solar AG (CH) | 2025-05-28 | — | — | EP | claimed |
| CN-119908477-A | A composition with anti-hangover effect and its preparation method | 安徽中科医疗器械有限公司 | 2025-05-02 | — | — | CN | claimed |
| CN-119656122-A | Dapagliflozin and metformin sustained release tablet and preparation method thereof | 山东康美乐医药科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119385924-A | Recombinant collagen female bacterial inhibition gel and preparation method thereof | 吉林省司诺健康实业集团有限公司 | 2025-02-07 | — | — | CN | claimed |
| WO-2025012749-A1 | SEMICONDUCTOR ASSEMBLIES AND METHODS FOR COOLING A SEMICONDUCTOR ASSEMBLY AND A METHOD FOR MANUFACTURING A SEMICONDUCTOR ASSEMBLY | CORINTIS SA (CH) | 2025-01-16 | — | — | WO | claimed |
| WO-2011060290-A2 | IMMEDIATE RELEASE TABLET FORMULATIONS | Bristol-Myer Squibb Company (US) | 2011-05-19 | — | — | WO | claimed |
| US-20110003757-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING FATTY LIVER DISEASE | ASTELLAS PHARMA INC. (JP) | 2011-01-06 | — | — | US | claimed |
| US-7851502-B2 | Dapagliflozin propylene glycol hydrate; diabetes; immediate release; sodium dependent glucose transporter (SGLT2) inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-14 | — | — | US | claimed |
| EP-2236137-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF FATTY LIVER DISEASES | Astellas Pharma Inc. (JP) | 2010-10-06 | — | — | EP | claimed |
| CN-101686988-A | Pharmaceutical formulation containing dapagliflozin propylene glycol hydrate | BRISTOL MYERS SQUIBB | 2010-03-31 | — | — | CN | claimed |
| EP-2139494-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DAPAGLIFLOZIN PROPYLENE GLYCOL HYDRATE | Bristol-Myers Squibb Company (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008116179-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DAPAGLIFLOZIN PROPYLENE GLYCOL HYDRATE | BRISTOL-MYERS SQUIBB (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080234367-A1 | Sodium dependent glucose transporter (SGLT2); such as dapagliflozin, dapagliflozin-PGS, a C-glucoside or an O-glucoside | BRISTOL-MYERS SQUIBB (US) | 2008-09-25 | — | — | US | claimed |
| US-20080234366-A1 | Dapagliflozin propylene glycol hydrate; diabetes; immediate release; sodium dependent glucose transporter (SGLT2) inhibitor | BRISTOL-MYERS SQUIBB (US) | 2008-09-25 | — | — | US | claimed |
| WO-2008116195-A2 | COMPOSITIONS COMPRISING AN SGLT2 INGIBITOR FOR TREATING OBESITY | BRISTOL-MYERS SQUIBB (US) | 2008-09-25 | — | — | WO | claimed |